NEW YORK (GenomeWeb News) – Shareholders of Tepnel Life Sciences have approved the acquisition of the firm by Gen-Probe.

Gen-Probe said today that more than 99 percent of Tepnel shareholders voted in favor of the deal, which was announced in late January. Under terms of the transaction, Gen-Probe will pay 27.1 pence ($.386) per share in cash for each share of Tepnel outstanding — valuing the deal at $132.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.